PET versus SPECT for determining myocardial tissue viability using fluorine-18-fluorodeoxyglucose

Frank V. Schraml, Daniel R. Driver, Thomas Randolph, Eugene D. Silverman

Research output: Contribution to journalArticlepeer-review


The U.S. Food and Drug Administration regulates the manufacture and distribution of 18F-FDG. Acquisition and use of this radiopharmaceutical for myocardial imaging at our institution required approval by our Institutional Review Board. Our initial objective was to present a scientific validation for use of this radiopharmaceutical in adjudicating the 'viable versus scarred myocardium question,' using either a PET scanner or a gamma camera equipped with 511-keV collimators. We believe that our nuclear medicine colleagues who find themselves in a similar business/legal situation regarding the acquisition and use of 18F-FDG will find this review useful. We reviewed the literature to document the efficacy of 18F-FDG, in general, in assessing myocardial viability. We then did a literature-based comparison of PET scanner methodology versus modified gamma camera methodology for imaging 18F-FDG emissions. Imaging 18F-FDG with a modified gamma camera appears to be an effective alternative to imaging with a standard PET camera for assessing myocardial viability.

Original languageEnglish (US)
Pages (from-to)272-274
Number of pages3
JournalJournal of Nuclear Medicine Technology
Issue number4
StatePublished - Dec 1997
Externally publishedYes


  • Fluorine-18-fluorodeoxyglucose
  • Gamma camera
  • Myocardial viability
  • Positron emissions

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'PET versus SPECT for determining myocardial tissue viability using fluorine-18-fluorodeoxyglucose'. Together they form a unique fingerprint.

Cite this